atorvastatin has been researched along with Aneurysm, Coronary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, MS; Bainto, E; Best, BM; Burns, JC; Cohen, HJ; Dominguez, SR; Duxbury, EH; Franco, A; Glodé, MP; He, F; Heizer, H; Jain, S; Jone, PN; Padilla, RL; Pancheri, J; Printz, B; Shimizu, C; Tremoulet, AH; Whitin, JC | 1 |
| Chahal, N; Manlhiot, C; McCrindle, BW; Niedra, E; Yeung, RS | 1 |
| Tremoulet, AH | 1 |
| Manlhiot, C; McCrindle, BW | 1 |
| Blankier, S; Ito, S; McCrindle, BW; Yeung, RS | 1 |
1 trial(s) available for atorvastatin and Aneurysm, Coronary
| Article | Year |
|---|---|
Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.
Topics: Administration, Oral; Adolescent; Atorvastatin; Child; Child, Preschool; Coronary Aneurysm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mucocutaneous Lymph Node Syndrome | 2019 |
4 other study(ies) available for atorvastatin and Aneurysm, Coronary
| Article | Year |
|---|---|
Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms.
Topics: Administration, Oral; Anthropometry; Anti-Inflammatory Agents; Atorvastatin; Canada; Child; Child Development; Cholesterol; Coronary Aneurysm; Coronary Vessels; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver Function Tests; Male; Medical Records, Problem-Oriented; Mucocutaneous Lymph Node Syndrome; Pyrroles; Retrospective Studies | 2014 |
Comment on atorvastatin safety in kawasaki disease patients with coronary artery aneurysms.
Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles | 2014 |
Author reply to comment on "atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms".
Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles | 2014 |
The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.
Topics: Animals; Antigens, Bacterial; Arteritis; Atorvastatin; Cell Wall; Coronary Aneurysm; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lacticaseibacillus casei; Lymphocyte Activation; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mucocutaneous Lymph Node Syndrome; Pyrroles; Specific Pathogen-Free Organisms; Superantigens; Tumor Necrosis Factor-alpha | 2011 |